These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35257740)

  • 1. A Randomized, Controlled Trial to Investigate the Efficacy of Nebulized Poractant Alfa in Premature Babies with Respiratory Distress Syndrome.
    Dani C; Talosi G; Piccinno A; Ginocchio VM; Balla G; Lavizzari A; Stranak Z; Gitto E; Martinelli S; Plavka R; Krolak-Olejnik B; Lista G; Spedicato F; Ciurlia G; Santoro D; Sweet D;
    J Pediatr; 2022 Jul; 246():40-47.e5. PubMed ID: 35257740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nebulized Poractant Alfa Reduces the Risk of Respiratory Failure at 72 Hours in Spontaneously Breathing Surfactant-Deficient Newborn Piglets.
    Rey-Santano C; Mielgo VE; Gomez-Solaetxe MA; Bianco F; Salomone F; Loureiro B
    Crit Care Med; 2020 Jun; 48(6):e523-e531. PubMed ID: 32301841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.
    Sinha SK; Lacaze-Masmonteil T; Valls i Soler A; Wiswell TE; Gadzinowski J; Hajdu J; Bernstein G; Sanchez-Luna M; Segal R; Schaber CJ; Massaro J; d'Agostino R;
    Pediatrics; 2005 Apr; 115(4):1030-8. PubMed ID: 15805381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic Surfactant CHF5633 Compared with Poractant Alfa in the Treatment of Neonatal Respiratory Distress Syndrome: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial.
    Ramanathan R; Biniwale M; Sekar K; Hanna N; Golombek S; Bhatia J; Naylor M; Fabbri L; Varoli G; Santoro D; Del Buono D; Piccinno A; Dammann CE
    J Pediatr; 2020 Oct; 225():90-96.e1. PubMed ID: 32553868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From bench to bedside: in vitro and in vivo evaluation of a neonate-focused nebulized surfactant delivery strategy.
    Bianco F; Ricci F; Catozzi C; Murgia X; Schlun M; Bucholski A; Hetzer U; Bonelli S; Lombardini M; Pasini E; Nutini M; Pertile M; Minocchieri S; Simonato M; Rosa B; Pieraccini G; Moneti G; Lorenzini L; Catinella S; Villetti G; Civelli M; Pioselli B; Cogo P; Carnielli V; Dani C; Salomone F
    Respir Res; 2019 Jul; 20(1):134. PubMed ID: 31266508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or beractant for respiratory distress syndrome.
    Fujii A; Allen R; Doros G; O'Brien S
    J Perinatol; 2010 Oct; 30(10):671-6. PubMed ID: 20336077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nebulization of High-Dose Poractant Alfa in Newborn Piglets on Nasal Continuous Positive Airway Pressure Yields Therapeutic Lung Doses of Phospholipids.
    Nord A; Bianco F; Salomone F; Ricci F; Schlun M; Linner R; Cunha-Goncalves D
    Am J Perinatol; 2022 Jul; 39(9):1001-1007. PubMed ID: 33242911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome.
    Fujii AM; Patel SM; Allen R; Doros G; Guo CY; Testa S
    J Perinatol; 2010 Oct; 30(10):665-70. PubMed ID: 20336076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-Response Study on Surfactant Nebulization Therapy During Nasal Continuous Positive Airway Pressure Ventilation in Spontaneously Breathing Surfactant-Deficient Newborn Piglets.
    Rey-Santano C; Mielgo V; Gomez-Solaetxe MA; Ricci F; Bianco F; Salomone F; Loureiro B
    Pediatr Crit Care Med; 2020 Jul; 21(7):e456-e466. PubMed ID: 32195907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of two different early rescue surfactant treatments on mortality in preterm infants with respiratory distress syndrome.
    Kadıoğlu Şimşek G; Kanmaz Kutman HG; Canpolat FE; Oğuz ŞS
    Clin Respir J; 2020 Mar; 14(3):285-290. PubMed ID: 31814293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of surfactant-TA, calfactant and poractant alfa for preterm infants with respiratory distress syndrome: a retrospective study.
    Jeon GW; Oh M; Sin JB
    Yonsei Med J; 2015 Mar; 56(2):433-9. PubMed ID: 25683992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nebulised surfactant to reduce severity of respiratory distress: a blinded, parallel, randomised controlled trial.
    Minocchieri S; Berry CA; Pillow JJ;
    Arch Dis Child Fetal Neonatal Ed; 2019 May; 104(3):F313-F319. PubMed ID: 30049729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The OPTIMIST-A trial: evaluation of minimally-invasive surfactant therapy in preterm infants 25-28 weeks gestation.
    Dargaville PA; Kamlin CO; De Paoli AG; Carlin JB; Orsini F; Soll RF; Davis PG
    BMC Pediatr; 2014 Aug; 14():213. PubMed ID: 25164872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Minimally Invasive Surfactant Therapy vs Sham Treatment on Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome: The OPTIMIST-A Randomized Clinical Trial.
    Dargaville PA; Kamlin COF; Orsini F; Wang X; De Paoli AG; Kanmaz Kutman HG; Cetinkaya M; Kornhauser-Cerar L; Derrick M; Özkan H; Hulzebos CV; Schmölzer GM; Aiyappan A; Lemyre B; Kuo S; Rajadurai VS; O'Shea J; Biniwale M; Ramanathan R; Kushnir A; Bader D; Thomas MR; Chakraborty M; Buksh MJ; Bhatia R; Sullivan CL; Shinwell ES; Dyson A; Barker DP; Kugelman A; Donovan TJ; Tauscher MK; Murthy V; Ali SKM; Yossuck P; Clark HW; Soll RF; Carlin JB; Davis PG;
    JAMA; 2021 Dec; 326(24):2478-2487. PubMed ID: 34902013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surfactant nebulization therapy during NIPPV ventilation in surfactant-deficient newborn piglets.
    Rey-Santano C; Mielgo V; Gastiasoro E; Bianco F; Salomone F; Gomez-Solaetxe MA
    Pediatr Pulmonol; 2021 Jul; 56(7):2125-2135. PubMed ID: 33960742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The short-term outcome of a large cohort of very preterm infants treated with poractant alfa (Curosurf) for respiratory distress syndrome. A postmarketing phase IV study.
    Lamboley-Gilmert G; Lacaze-Masmonteil T;
    Paediatr Drugs; 2003; 5(9):639-45. PubMed ID: 12956620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poractant alfa versus beractant for respiratory distress syndrome in preterm infants: a retrospective cohort study.
    Paul S; Rao S; Kohan R; McMichael J; French N; Zhang G; Simmer K
    J Paediatr Child Health; 2013 Oct; 49(10):839-44. PubMed ID: 23802801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, controlled trial of poractant alfa versus beractant in the treatment of preterm infants with respiratory distress syndrome.
    Dizdar EA; Sari FN; Aydemir C; Oguz SS; Erdeve O; Uras N; Dilmen U
    Am J Perinatol; 2012 Feb; 29(2):95-100. PubMed ID: 22105435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poractant alfa versus bovine lipid extract surfactant for infants 24+0 to 31+6 weeks gestational age: A randomized controlled trial.
    Lemyre B; Fusch C; Schmölzer GM; Rouvinez Bouali N; Reddy D; Barrowman N; Huneault-Purney N; Lacaze-Masmonteil T
    PLoS One; 2017; 12(5):e0175922. PubMed ID: 28472058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nebulization of Poractant alfa via a vibrating membrane nebulizer in spontaneously breathing preterm lambs with binasal continuous positive pressure ventilation.
    Hütten MC; Kuypers E; Ophelders DR; Nikiforou M; Jellema RK; Niemarkt HJ; Fuchs C; Tservistas M; Razetti R; Bianco F; Kramer BW
    Pediatr Res; 2015 Dec; 78(6):664-9. PubMed ID: 26322413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.